摘要
AIM:To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer(EC)risk using meta-analysis. METHODS:All eligible studies published before March 1,2010 were selected by searching PubMed using keywords"p53"or"TP53","polymorphism"or"variation", "esophageal"and"cancer"or"carcinoma".Crude odds ratios(ORs)with 95%confidence intervals(CIs)were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed-and random-effects models. RESULTS:Nine case-control studies involving 5545 subjects were included in this meta-analysis.Significantly reduced risk of EC was associated with TP53genotypes for Arg/Arg+Arg/Pro vs Pro/Pro(OR= 0.73,95%CI:0.57-0.94,P=0.014).Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have populationbased controls(Arg/Arg vs Pro/Pro:OR=0.56,95% CI:0.47-0.66,P<0.001),and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P <0.001)or include at least 200 subjects(Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P<0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC(Arg/Arg vs Pro/Pro:OR=0.54,95%CI:0.46-0.64,P<0.001). CONCLUSION:TP53 Arg72 carriers are significantly associated with decreased EC risk.Nevertheless,more welldesigned studies are needed to confirm our findings.
AIM：To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer（EC）risk using meta-analysis. METHODS：All eligible studies published before March 1,2010 were selected by searching PubMed using keywords＂p53＂or＂TP53＂,＂polymorphism＂or＂variation＂, ＂esophageal＂and＂cancer＂or＂carcinoma＂.Crude odds ratios（ORs）with 95%confidence intervals（CIs）were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed-and random-effects models. RESULTS：Nine case-control studies involving 5545 subjects were included in this meta-analysis.Significantly reduced risk of EC was associated with TP53genotypes for Arg/Arg＋Arg/Pro vs Pro/Pro（OR= 0.73,95%CI：0.57-0.94,P=0.014）.Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have populationbased controls（Arg/Arg vs Pro/Pro：OR=0.56,95% CI：0.47-0.66,P0.001）,and use white blood cells or normal tissue to assess TP53 genotypes of cases （Arg/Arg vs Pro/Pro：OR=0.56,95%CI：0.47-0.65,P 0.001）or include at least 200 subjects（Arg/Arg vs Pro/Pro：OR=0.56,95%CI：0.47-0.65,P0.001）. Analysis restricted to well-designed studies also supported the significantly decreased risk of EC（Arg/Arg vs Pro/Pro：OR=0.54,95%CI：0.46-0.64,P0.001）. CONCLUSION：TP53 Arg72 carriers are significantly associated with decreased EC risk.Nevertheless,more welldesigned studies are needed to confirm our findings.
基金
Supported by the National 973 Program of China(No.2004CB518605)
the National 863 Project of China(No.2006AA020501)
the National Key Sci-Tech Special Project of China(No.2008ZX10002-020)
the Project of the Shanghai Municipal Science and Technology Commission(03dz14086)
the National Natural Science Foundation of China(No.30024001and 30771188)
